<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910813-0029</DOCNO><DOCID>910813-0029.</DOCID><HL>   Business Brief -- Upjohn Co.:   Firm Buys Biological Unit   Of Fermenta Animal Health</HL><DATE>08/13/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C10</SO><CO>   UPJ</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>EUROPE (EU)MICHIGAN (MI)MISSOURI (MO)NEBRASKA (NE)NETHERLANDS (NL)NORTH AMERICA (NME)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   Upjohn Co. said it purchased the biological portion ofFermenta Animal Health Co., a subsidiary of FermentaNetherlands B.V. in Kansas City, Mo. It will become part ofOxford Veterinary Laboratories Inc., a subsidiary of Upjohn.Terms of the sale were not disclosed.   The pharmaceutical company, based in Kalamazoo, Mich.,said the acquisition fits the long-term strategy of itsanimal health business to expand into the biological marketutilizing Oxford Laboratories.</LP><TEXT>   Included in the purchase agreement is Fermenta's entirebiological business, including a line of bovine and smallanimal vaccine products, and a production plant in Omaha,Neb.</TEXT></DOC>